

Sandeep Vijan, MD, MS  
Associate Professor of Internal Medicine  
University of Michigan Health System  
Center for Clinical Management Research  
Ann Arbor VA HSR&D Center of Excellence  
2215 Fuller Road, Mailstop 11H  
Ann Arbor, MI 48105-2399  
(734) 845-3635  
[svijan@umich.edu](mailto:svijan@umich.edu)

## **CURRICULUM VITAE**

### **Education and Training**

#### Education

- 9/1981-6/1985     Diploma, Athens High School, Troy, Michigan
- 9/1985-5/1989     B.S., University of Michigan, Ann Arbor, Michigan
- 7/1988-5/1992     M.D., University of Michigan, Ann Arbor, Michigan
- 9/1995-6/1997     M.S. in Clinical Research Design and Statistical Analysis  
University of Michigan School of Public Health and Rackham School of  
Graduate Studies, Ann Arbor, Michigan

#### Postdoctoral Training

- 6/1992-7/1995     Residency, Department of Internal Medicine, University of  
Michigan Medical Center, Ann Arbor, Michigan

### **Certification and Licensure**

#### Medical Licensure

- Board of Medicine Physician License, State of Michigan (#4301059382)  
*Expires 01/31/2009*
- Board of Pharmacy Controlled Substance License, State of Michigan (#4301059382)  
*Expires 01/31/2009*
- Controlled Substance Certificate, Drug Enforcement Administration (#BV4843808)  
*Expires 05/31/2011*

#### Board Certification

- American Board of Internal Medicine, 2005-Present

### Other Certification

BLS Certificate, American Heart Association  
*Expires 08/2010*

## **Academic, Administrative, and Clinical Appointments**

### Academic Appointments

- |                |   |
|----------------|---|
| 7/1995-6/1997  | AHCPR Health Services Research Fellow, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan |
| 7/1997-present | Investigator, Veterans' Administration Health Services Research and Development, Ann Arbor, Michigan  |
| 7/1997-6/1999  | Lecturer, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan                              |
| 9/1999-9/2006  | Assistant Professor, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan                   |
| 9/2006-present | Associate Professor, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan                   |

### Administrative Appointments

- |               |   |
|---------------|---|
| 7/1998-6/2001 | Associate Director, Michigan Diabetes Research and Training Center, Modeling Core |
|---------------|---|

### Clinical Appointments

- |                |  |
|----------------|--|
| 7/1995-present | Staff Physician, Ann Arbor Veterans Administration Health System |
| 7/1997-present | Staff Physician, University of Michigan Health System            |

## **Research Interests**

1. Health Outcomes
2. Health Policy
3. Health Economics

## Grants

### Current

IIR 06-253 (S Vijan) 01/01/08-12/31/10  
VA HSR&D Merit Program \$411,200

#### **Improving quality measurement using quality adjusted life years.**

This grant will examine how individualized risk and benefit assessment can be used to improve our measures of quality of care in patients with diabetes. Specifically, it uses modeling techniques to estimate potential losses in quality-adjusted life-years to define quality of care.

Role: Principal Investigator

IIR 06-205 (S Hawley/S Vijan) 01/01/08-12/31/10  
VA HSR&D \$2,428,267

#### **Evaluating a preference-based intervention for increasing colorectal cancer screening**

This project examines whether a preference-elicitation tool for colorectal cancer screening can improve screening adherence.

Role: Co-Principal Investigator

R56 DK74717-01 (Tuncelli) 08/01/07-07/31/09  
National Institutes of Health \$13,119

#### **The Impact of Diabetes Control on Employment and Work Productivity**

This project examines the relationship between diabetes risk factor control (HbA1c, cholesterol, and blood pressure levels) and employment and productivity outcomes. This allows us to better understand the full economic consequences of diabetes, and whether there is a relationship between improved treatment and economic outcomes.

Role: Site Principal Investigator

RWJ 59964 (R Hayward) 07/01/07-06/30/08  
Robert Wood Johnson Foundation \$1,015,000

#### **Clinical Scholars Program**

Training grant in translational research for clinician-investigators.

Role: Co-Investigator

R01 CA106773 (J Inadomi) 08/16/06-01/31/10  
NIH, National Cancer Institute \$839,800

#### **The Effect of Patient Adherence on the Cost-Effectiveness of Screening for Colorectal Neoplasia**

This project examines patient adherence to various strategies for colorectal cancer screening, and how differences in adherence affect the incremental cost-effectiveness of different screening tests.

Role: Site Principal Investigator

IIR 04-239 (M Heisler/ J Piette)  
VA HSR&D

04/01/06-03/31/10  
\$999,611

**Telephone Peer Support for Insulin Management among VA Diabetes Patients**

This randomized intervention examines the use of peer-to-peer communication and support, using IVR technology, on clinical outcomes in patients with type 2 diabetes. Outcomes of interest are the initiation of insulin therapy and glucose control.

Role: Co-Investigator

DIB-98-001 (E Kerr)  
VA HSR&D

10/01/04 – 09/30/08  
\$1,750,000

**Quality Enhancement Research Initiative – Diabetes Mellitus (QUERI-DM)**

The objectives of the Quality Enhancement Research Initiative for Diabetes Mellitus are 1) to establish an on-going process for identifying and facilitating the implementation of efficient approaches to improving processes of care, which are proven to have an effect on important health outcomes for veterans with diabetes; and 2) improve our understanding of barriers to system wide quality improvement initiatives so as to inform future QUERI initiatives and aid other initiatives related to diabetes care both within and outside of the VHA. The current submission is a continuation of this project.

Role: Co-Investigator

5 P50 DK 20572 (W Herman)  
NIH/NIDDK

12/01/02-11/30/13  
\$8,912,285

**Michigan Diabetes Research Training Center**

The major goals of the Diabetes Research and Training Center are to meet the needs of investigators and thereby support and strengthen the University's interdepartmental activities in research, training and outreach in the field of diabetes, its complications, and related endocrine and metabolic disorders.

Role: Core Investigator

HFP 83-014 (R Hayward)  
VA Ann Arbor HSR&D

10/01/01-09/30/12  
\$7,000,000

**VA Center for Practice Management & Outcomes Research**

Ongoing Health Services Research & Development Center of Excellence grant.

Role: Co-Investigator

Pending

NIH P01

“The Value of Interventions for Depression in the Elderly - Expanding the National Health Accounts” Program Project

PI – Allison Rosen, MD

Role - Core Investigator, Modeling Core

10/01/2008 – 09/30/2013

Total \$1,500,000

NIH P01

“The Value of Interventions for Depression in the Elderly - Expanding the National Health Accounts” Program Project 3

PI – Allison Rosen, MD

Role - Co-Investigator

Total \$2,000,000

10/01/2008 – 09/30/2013

NIH P01

“The Value of Interventions for Depression in the Elderly - Expanding the National Health Accounts” Program Project 5

Role - Principal Investigator

Total \$1,350,000

10/01/2008 – 09/30/2013

AHRQ R21 HS017651

“Optimizing colorectal cancer screening in the complex patient”

PI – Carmen Lewis, MD

Role - Co-Investigator

08/01/2008 – 8/01/2010

Total \$250,000

#### Completed

VA HSR&D RRP 06-189

“Patient preferences and endoscopy demand in VHA”

Role - Principal Investigator

Total \$31,611

04/01/2007 - 09/30/2007

Veterans Administration DIB 98-001

“Quality Enhancement Research Initiative, Diabetes.”

PI - Rodney A. Hayward. Role – Consultant.

Total \$200,000 annually (renewable).

10/1/2006-9/30/2007

VA HSR&D IIR 04-176

“Insulin Treatment Variation in Southwestern Diabetics: Therapeutic Decision-making.”

PI - Martha Jane Mohler, Tucson VA. Role - Co-Investigator

Total \$448,200

05/01/2005 – 04/30/2008

National Institutes of Health, National Cancer Institute. Grant 1 R01 CA106782-01.

“The cost-effectiveness of genetic screening for colon cancer”

Role - Principal Investigator

Total \$450,000 (Funded on first submission, percentile score = 9.5)

06/05/2004 - 05/31/2008

Henry Ford Health System  
Subcontract Commonwealth Fund  
“Modeling the health impacts of disparities in diabetes care”  
PI - David Nerentz, PhD.  
Role – Co-Principal Investigator  
Total \$17, 950  
01/01/2004 - 06/30/2004.

Kaiser Permanente Northern California  
National Institutes of Health, Department of Health & Human Services Subcontract  
“Measuring the clinical benefit and value of diabetes care”  
Role - Principal Investigator  
Total \$45,000  
07/01/2004 – 06/30/2005

Veterans Administration QUERI  
“An Evaluation of a Coordinated Proactive Diabetes Eye Care Program”  
PI – Steven Bernstein  
Role - Co-Investigator  
Total \$499,595  
01/02/2004 – 12/31/2005

Social Security Administration/Michigan Retirement Research Center grant 02-12  
“Implications of High Risk Health Behaviors on Work-Force Participation: Disability, Retirement, and Lost Productivity”  
PI – Caroline Richardson. Role - Co-Investigator  
Total \$50,000  
01/01/2003 – 12/31/2003

Michigan Department of Community Health, contract #20011001  
“Evaluating a web-based tailored information and feedback program to improve colon cancer screening rates in the primary care setting: A randomized controlled trial”  
PI – Steven Katz. Role - Co-Investigator  
Total \$240,000  
01/01/2002 – 12/31/2002 (no cost-extension ongoing through 12/31/03)

Veterans Administration Mentored Career Development Award  
“Diabetes Care: Optimizing Quality, Minimizing Risk”

Role - Principal Investigator  
100% salary support for 3 years  
01/01/2001 – 12/31/2004

Social Security Administration/Michigan Retirement Research Center UM01-11  
“The impact of chronic diseases on work-force participation”  
Role - Principal Investigator  
Total \$100,000  
10/01/2000 – 09/30/2001 (effort donated as of 1/1/01)

Michigan Department of Community Health, Contract #20011001  
“Developing Electronic Communications-Based Interventions Between Patients and Providers to Improve Cancer Control in the Primary Care Setting”  
PI – Steven Katz, MD  
Role - Co-Investigator  
Total \$138,500  
10/01/2000 – 09/30/2001

University of Michigan Faculty Group Practice Academic Venture Investment Fund  
VIF.FY99.065  
“Proactive Identification of Patients At-Risk for High Utilization: *Using the MCDR Telephone Interview.*”  
PI – Marcia Valenstein, MD  
Role - Co-Investigator  
Total \$178,917  
02/01/2000 – 01/31/2002

Veterans Administration HSR&D IIR 970781  
“Patient Preferences and the Care of Diabetes”  
Role - Principal Investigator  
Total \$284,380  
09/01/1998 - 03/01/2001

Veterans Administration HSR&D IIR 970771  
“Proactive Diabetes Case Management”  
PI – Sarah Krein, PhD  
Role - Co-Investigator  
Total \$749,940  
09/01/1998 – 08/31/2001

## **Honors and Awards**

1994-1995	House Officer Research Award, Department of Internal Medicine, University of Michigan.
1996	Outstanding Research Award, Midwest Society of General Internal Medicine.
1997	Top 10 abstract, University of Michigan Research Day.
1997	Outstanding Research Award, Midwest Society of General Internal Medicine.
2004-2007	Chair, VA HSR&D Scientific Merit Review Board, Implementation and Management Section.
2006	Elected to Central Society for Clinical Research.
2008	Chair, VA HSR&D Scientific Merit Review Board, Improving Healthcare Processes Section

## **Memberships in Professional Societies**

1989-1992	American Medical Student Association.
1994-present	Member, American College of Physicians.
1996-present	Society of General Internal Medicine.

## **Editorial Positions, Boards, and Peer-Review Service**

### Study Sections

2001-2003	Veterans Affairs Quality Enhancement Research Initiative.
2004-present	Chair, Veterans Affairs Health Services Research & Development Scientific Review and Evaluation Board (Implementation and Management Research).

### Editorial Boards

2004-present	Medical Care Research and Review
--------------	----------------------------------

### Manuscript review

1997-2007	Diabetic Medicine
1997-2007	Diabetologia
1997-2007	Gastroenterology



1997-2007	The Lancet
1997-2007	Pharmacoeconomics
1997-2007	American Journal of Gastroenterology
1997-2007	Medical Decision Making
1997-present	American Journal of Managed Care
1997-present	American Journal of Medicine
1997-present	Annals of Internal Medicine
1997-present	Archives of Internal Medicine
1997-present	Diabetes Care
1997-present	Journal of the American College of Cardiology
1997-present	Journal of the American Medical Association
1997-present	Journal of General Internal Medicine
1997-present	Medical Care
1997-present	Translational Research

## Teaching

### Teaching activities

1996	Management of Type 2 Diabetes lecture, University of Michigan Primary Care Conference.
1996-present	House officer mentor, Veterans Administration Primary Care Clinic, Ann Arbor, Michigan (rated in top quintile of faculty by residents, 2002-2004, received teaching bonus in 2003, 2004).
1996-present	Discussion leader, health policy sequence, second year medical Students Topic: physician supply issues.
1996-present	Discussion leader, health policy sequence, second year medical students Topic: guideline development and dissemination.
1996-2002	Discussion leader, second year medical students, endocrinology sequence. Topic: Evaluation of the medical literature.
1996-present	Discussion leader, "Critical Appraisal of the Medical Literature," fourth year medical students. Topic: guideline evaluation.
1997-1998	Discussion leader, problem-based learning ethics sequence, Introduction to the Patient, first year medical students.
1997-present	Attending physician, inpatient morning report.

1997-present	Attending rounds, inpatient medical service, Veterans Administration Medical Center.
1998-2000	Discussion leader, health policy sequence, second year medical students. Topic: The changing role of physicians under managed care.
1998-present	Attending physician, Chief of Medicine Rounds.
1998-2000	Attending physician, residents' journal club
1999-present	Attending physician, intern report.
1997-1998	Ambulatory care conference on critical appraisal and interpretation of the medical literature.
1998-present	Instructor, Robert Wood Johnson Clinical Scholars Summer Session.
1998, 2003, 2005, 2006	Noon conference, "Update in diabetes management".
1998	Management of Diabetes Mellitus (Update). Co-author. Audience: primary care clinicians and other health care providers who treat adults with this condition. (Available through the UM CME web site: <a href="http://cme.med.umich.edu">cme.med.umich.edu</a> ).
1999, 2001 2003	Noon conference, "Screening for cancer in primary care".
1999, 2001 2003	University of Michigan Grand Rounds, 2000. "Risk stratification in medicine: application of clinical predictors of risk to clinical decision-making"
2000, 2004	Lecturer, M2 Gastrointestinal sequence, "Colorectal cancer screening".
2004	Evidence-based management of hypertension in type 2 diabetes. American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.
2004	Evidence-based management of lipids in type 2 diabetes. American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.
2003, 2004	Setting appropriate standards of care in type 2 diabetes.

American College of Physicians. Philadelphia, PA, October 2003; October 2004.

2004            Adult Preventive Health Care: Cancer Screening (update). Co-author. Audience: primary care clinicians and other health care providers who treat adults with this condition. (Available through the UM CME web site: [cme.med.umich.edu](http://cme.med.umich.edu)).

2004            Management of Type 2 Diabetes Mellitus (Update). Co-author. Audience: primary care clinicians and other health care providers who treat adults with this condition. (Available through the UM CME web site: [cme.med.umich.edu](http://cme.med.umich.edu)).

2007-present    Ambulatory Care Curriculum, Evidence-based medicine instructor for internal medicine interns

#### Mentoring Faculty

2005- present    Junior faculty mentor, Allison Rosen, MD.  
Revising the national health accounts; Examining the effects of reimbursement policy on diabetes and CHD outcomes. NIH K-08 award mentor, re-submission date 2/2008.

2006-present    Junior faculty mentor, Joyce Lee, MD.  
Modeling the effects of obesity on diabetes incidence and health care utilization. NIH K-08 award mentor; start date 1/2008.

2006-present    Junior faculty mentor, Kara Bambauer, PhD.  
Estimating the cost-effectiveness of treatment strategies for depression; Estimating the effects of depression on employment outcomes. VA HSR&D Career Development Award mentor; start date 10/1/2008.

2005-present    Junior faculty mentor, Kaan Tunceli, PhD.  
Diabetes Control, Employment, and Work Productivity.

2006-present    Junior faculty mentor, Joe Norman, MD, PhD, 2006.  
Improving multivariate sensitivity analysis for decision analytical models.

2007-present    Junior faculty mentor, Fu Luan, MD, 2007-present. Molecular markers and risk-stratification in transplantation.

2008-present    Junior faculty mentor, Sameer Saini, MD. Measuring and improving quality of care in endoscopy.

#### Mentoring Fellows

2001-2003       Fellowship mentor, Peter Cram, MD, MBA.

Cost-effectiveness of external defibrillators; effects of celebrity spokespeople on health behaviors.

- 2001-2002 Fellowship mentor, Michele Heisler, MD, MPA.  
Patient and provider concordance on priorities in diabetes care.
- 2003-2005 Fellowship mentor, Allison Rosen, MD, ScD.  
Should Medicare cover ACE inhibitors for patients with diabetes? A cost-utility analysis. *Winner of best paper, Society for Medical Decision Making, 2005-6.*
- 2004-2007 Fellowship mentor, Paul Chan, MD.  
Effectiveness and costs of catheter ablation of atrial fibrillation; effectiveness of ICDs in clinical practice; cost-effectiveness of risk-stratifying ICD implantation. *Winner of ACC young investigator award for best presentation, ACC conference, 2006. Winner of award for best paper in Journal of the American College of Cardiology, 2006.*
- 2004-2007 Fellowship mentor, Sameer Saini, MD.  
Effectiveness of surveillance colonoscopy for colorectal cancer; Colorectal cancer screening in women; Pay-for-performance and colorectal cancer screening.
- 2006-2007 Fellowship mentor, Michael Volk, MD.  
Effectiveness of allocation strategies for liver transplantation.
- 2006-2007 Fellowship mentor, Cheerag Patel, MD.  
Cost-effectiveness of side airbag deployment in the US.

#### Mentoring Residents

- 1999 Senior research project mentor, Erik-Jan Wamsteker, M.D.  
Cost-effectiveness of carotid endarterectomy in symptomatic patients with 50-69% stenoses
- 2001-2002 Senior research project mentor, Jim Lavelle, M.D.  
Predictors of positive blood cultures in patients admitted with community-acquired pneumonia.
- 2002-2003 Senior research project mentor, David Deguzman, M.D.  
Adherence and follow-up of fecal occult-blood testing for colorectal cancer screening.
- 2002-2003 Senior research project mentor, Gregory Bump, M.D.  
The impact of chronic diseases on self-management of type 2 diabetes.

2003-2004	Senior research project mentor, Ghazala Khan, M.D. Estimating the accuracy of echocardiography in predicting right ventricular systolic pressure.
2004-2006	Senior research project mentor, Sachin Parikh, M.D. Cost-effectiveness of electrophysiologic studies to stratify ICD implantation.

## **Committee, Organizational, and Volunteer Service**

### Veterans Administration Hospital

2003-2005	Chair, VA Ann Arbor Healthcare System Care Management Committee.
-----------	--

### University of Michigan Medical School:

1996-present	Chair/Project team leader, University of Michigan type 2 diabetes guidelines development team.
1998-present	University of Michigan preventive care guidelines: Colorectal cancer screening.

### National/International

1999	Review committee, US Preventive Services Task Force, Screening for Diabetes
2006	Review committee, Agency for Healthcare Research and Quality, Cost-effectiveness of stool DNA screening for colorectal cancer
1998-present	Author, ACP PIER module for the management of type 2 diabetes, American College of Physicians.
2004-present	Author, British Medical Journal Clinical Evidence, Management of hypertension in type 2 diabetes.
1998-1999	American Academy of Family Physicians and American Diabetes Association guidelines for glycemic control in type 2 diabetes.
1999	Assessing the Care of Vulnerable Elders, Type 2 Diabetes, RAND quality indicator development.
2000-2003	Abstract review committee, VA HSR&D Annual Meeting.
2001-present	American College of Physicians evidence review and guidelines for the management of hypertension in type 2 diabetes.

2002	Abstract review committee, National Association of Inpatient Physicians Annual Meeting,.
2002-2004	Abstract review committee, Society of General Internal Medicine National Meeting.
2002-present	American College of Physicians evidence review and guidelines for the management of lipids in type 2 diabetes.
2003	Abstract review committee, VA QUERI Annual Meeting.
2003, 2004	Abstract review committee, VA Office of Research and Development Annual Meeting.
2004	Panel member, National Institutes of Health consensus development conference on the management of celiac disease, June 28-30, 2004.
2004-2005	Chair, chronic disease workshop sub-committee, Society of General Internal Medicine National Meeting.
2004-2008	Chair, VA HSR&D Scientific Review and Evaluation Board, Implementation and Management Research section.
2004-present	Board member, VA HSR&D Field Based Scientific Advisory Board for Implementation and Management Research.
2005-2006	Chair, Chronic disease care and management scientific abstract committee, Society of General Internal Medicine National Meeting.
2006-present	Steering Committee member, National Diabetes Education Program, 2006.

#### Regional

1997-1998	Member, Greater Detroit Area Health Council Quality Forum Clinical Work Group, Diabetes sub-group.
1998	Member, Daimler-Chrysler Evidence-Based Medicine in Action, diabetes practice guideline development committee.

#### **Consulting Positions**

7/1998-present	American College of Physicians, PIER module for the management of type 2 diabetes
7/1999-present	American College of Physicians, treatment of cardiovascular risk factors in type 2 diabetes

- 11/2003-present BMJ Clinical Evidence; Treatment of hypertension in type 2 diabetes
- 12/2004-present American College of Physicians; Diabetes Care Improvement Initiative.
- 10/2005-present Harvard University Center for Health Systems Improvement, Expanding the National Health Accounts
- 10/2007-present GI View Limited, Economics of the Aeroscope

## **Visiting Professorships, Seminars, and Extramural Invited Presentations**

### Invited Presentations

*Cost-utility of screening for diabetic retinopathy.* Evidence-Base for a Disease Management Programme for Type 2 Diabetes. Frankfurt, Germany, January 2001. Sponsor: AOK-Bundesverband under the auspices of the European Diabetes Association (EASD).

*Rates, predictors, and costs of disability in patients with type 2 diabetes.* Michigan Retirement Research Council Health and Retirement Study seminar, January 2001.

*The impact of diabetes on work-force participation: results from a national sample.* Social Security Retirement Research Consortium Annual Conference, National Press Club, Washington DC, June 2002.

*Screening for colorectal cancer: an updated view of the literature.* Mackinac Island Internal Medicine Update, Mackinac Island, MI, August 2003.

*Prevention of cardiovascular disease in type 2 diabetes.* Mackinac Island Internal Medicine Update, Mackinac Island, MI, August 2003.

*Emerging paradigms in medicine: risk-stratifying screening for diabetic retinopathy.* Mackinac Island Internal Medicine Update, Mackinac Island, MI, August 2003.

*The cost-effectiveness of prevention of cardiovascular disease in type 2 diabetes.* Common Problems in Office Practice symposium, Dearborn, MI. April 2003.

*Evidence-based management of hypertension in type 2 diabetes.* American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.

*Evidence-based management of lipids in type 2 diabetes.* American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.

*Economic issues in diabetes-related vision impairment.* Centers for Disease Control, Economics of vision impairment: public health prevention opportunities. Atlanta GA, June 4, 2004.

*Moderator, quality of care abstract session.* SGIM Annual Meeting; Chicago, IL, May 2004.

*Moderator, diabetes abstract session.* VA HSR&D Annual Meeting; Washington, DC, March 2004.

*The cost-effectiveness of screening for colorectal cancer.* National Academy of Sciences, Institute of Medicine. Conference on Economic Modeling in Colorectal Cancer. Washington, DC, January 25-27, 2004.

*Setting appropriate standards of care in type 2 diabetes.* American College of Physicians. Philadelphia, PA, October 2003, October 2004.

*Cost-effectiveness of virtual colonoscopy for colorectal cancer screening.* 7<sup>th</sup> International Virtual Colonoscopy Symposium. Boston, MA, October 16, 2006.

*Moderator, Chronic Disease Management Abstract Session.* SGIM Annual Meeting; Los Angeles, CA, April 2006.

*Recommended LDL-C treatment targets for stable CHD or Diabetes Patients.* Guangzhou, China, City symposium, October 26, 2007.

*Recommended LDL-C treatment targets for stable CHD or Diabetes Patients.* Hangzhou, China, City symposium, October 25, 2007.

*Recommended LDL-C treatment targets for stable CHD or Diabetes Patients.* Shanghai, China, City symposium, October 24, 2007.

*Recommended LDL-C treatment targets for stable CHD or Diabetes Patients.* Nanjing, China, City symposium, October 23, 2007.

*Recommended LDL-C treatment targets for stable CHD or Diabetes Patients.* Beijing, China, City symposium, October 22, 2007.

*Lipid-lowering goals in coronary artery disease: how low should we go?* American College of Cardiology, Michigan chapter meeting, Traverse City, MI, October 6, 2007.

*The evidence for LDL-C targets in patients with diabetes.* American Diabetes Association Lipoprotein Consensus Conference, July 18, 2007.

#### Other Presentations



*Quality standards and the politics of medicine: How well-meaning people can cause blindness and death.* Robert Wood Johnson Clinical Scholars, University of Michigan, April 2000.

*Should we screen annually for diabetic retinopathy?* Ophthalmology Grand Rounds, University of Michigan, April 2000.

*The Importance of Patient Preferences when making treatment decisions in older patients.* The Challenge of Diabetes Care in Older Adults, University of Michigan, September 2001.

### Research experience

The Use of Inhaled Aminoglycosides in the Treatment of Nosocomial Pneumonia, Senior Research Project, April 1995

Oropharyngeal Bacterial Colonization in Nursing Home Patients, 1989

Research Fellow, Center for Practice Management and Outcomes Research, Ann Arbor Veterans Administration Medical Center, 1995-1997.

## **Bibliography**

### Peer Reviewed Publications

1. Vijan S, Stevens DL, Funnell MM, Greene DA, Harrison RV, Herman WH, Hiss RG, Martin CL, Piehl EJ, Ratliff BJ, Standiford CJ. Management of Type II Diabetes Mellitus. *Ann Arbor, MI: Office of Clinical Affairs, University of Michigan Health System*, 1996. [practice guideline]
2. Vijan S, Steven D, Herman WH, Funnell M, Standiford C. Prevention, Treatment, and Counseling for the Prevention of Complications in Type II Diabetes. Putting Evidence into Practice. *J Gen Intern Med* 1997; 12(9):567-580.[abstracted in ACP Journal Club 1998; 128(2).]
3. Vijan S, Hofer TP, Hayward RA. Estimated Benefits of Glycemic Control in Type 2 Diabetes. *Ann Intern Med* 1997; 127(9):788-795. [abstracted in Journal Watch 1997; 17 (23): 186-187]; [abstracted in American Journal of Managed Care 1998; 4(4): 480].
4. Goold SD, Vijan S. Normative Issues in Cost Effectiveness Analysis. *J Lab Clin Med* 1998; 132(5):376-382.
5. Vijan S, Stevens DL, Funnell MM, Greene DA, Harrison RV, Herman WH, Hiss RG, Martin CL, Piehl EJ, Ratliff BJ, Standiford CJ. Management of Diabetes Mellitus (Update). *Ann*

Arbor, MI: Office of Clinical Affairs, University of Michigan Health System, 1998. [Was available from the Agency for Healthcare Research and Quality at [www.guideline.gov](http://www.guideline.gov)] [practice guideline]

6. Vijan S, Kent DM, Hayward RA. Are randomized controlled trials sufficient evidence to guide clinical practice in type 2 diabetes mellitus? *Diabetologia* 2000;43:125-130.
7. Vijan S, Hofer TP, Hayward RA. A cost-utility analysis of screening intervals for diabetic retinopathy. *JAMA* 2000; 283(7):889-896. [abstracted in the Detroit News; Reuters health; CBShealthwatch.com; Healthscout.com; WebMD.com]
8. Hofer TP, Vijan S, Hayward RA. Effectiveness of screening for type 2 diabetes on prevention of microvascular complications. *Int Journal of Technol Assess Health Care* 2000;16(3):822-833
9. Vijan S. Are we overvaluing performance measures? *Eff Clin Pract* 2000; 3(5):247-249.
10. Valenstein M, Zeber J, Boehm K, Buttar A, Vijan S. Should we screen for depression in primary care?. A cost-utility analysis. *Ann Intern Med* 2001; 134:345-360.
11. Shekelle PG, Vijan S. Quality indicators for the management of diabetes mellitus in vulnerable elders. *Ann Intern Med* 2001; 135(8, part 2). Available at <http://www.acponline.org/sci-policy/acove/>
12. Kerr EA, Krein SL, Vijan S, Hayward RA. Avoiding pitfalls in chronic disease quality measurement: A case for the next generation of technical quality measure. *Am J Manag Care* 2001; 7(11):1033-1043.
13. Vijan S, Hwang E, Hofer TP, Hayward RA. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. *Am J Med* 2001; 111:593-601.
14. Nallamothu BK, Saint S, Ramsey S, Hofer TP, Vijan S, Eagle KA. The role of hospital volume in coronary artery bypass grafting: Is more always better? *J Am Coll Coll Card* 2001; 38:1923-1930.
15. Langa KM, Vijan S, Blaum C, Kabeto MU, Chernew ME, Hayward RA, Katz SJ, Willis RJ, Fendrick AM. The quantity and cost of informal caregiving for the elderly with diabetes: estimates from a nationally representative sample. *J Gerontol* 2002; 57B:S177-S186.
16. Krein SL, Vijan S, Pogach LM, Hogan MM, Kerr EA. Aspirin use and counseling about aspirin among patients with diabetes in VA. *Diabetes Care* 2002; 25:965-970.
17. Kent DM, Griffith JL, Hayward RA, Vijan S, Beshansky J, Califf RM, Selker HP. An independently-derived model for selecting patients likely to benefit from tissue plasminogen activator: Validating with GUSTO. *Am J Med* 2002; 113:104-111.

18. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes: Blood pressure goals, choice of agents, and setting priorities in diabetes care. *Ann Intern Med* 2003; 138:593-602. [abstracted by WebMD.com]
19. Cram P, Vijan S, Wolbrink A, Fendrick AM. The impact of including passive benefits in cost-effectiveness analysis: The case of automated external defibrillators on commercial aircraft. *Value in Health* 2003; 6(4):466-473.
20. Cram P, Inadomi J, Cowen ME, Carpenter D, Fendrick AM, Vijan S. The impact of a healthy celebrity spokesperson on preventive health behavior: the Katie Couric effect. *Arch Intern Med* 2003; 163(13):1601-1605.
21. Cram P, Vijan S, Fendrick AM. Cost-effectiveness of automated external defibrillation deployment in selected public locations. *J Gen Intern Med* 2003;18(9):745-754.
22. Heisler M, Vijan S, Anderson RM, Ubel PA, Bernstein SJ, Hofer TP. When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make? *J Gen Intern Med* 2003; 18(11):893-902.
23. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus. *Ann Intern Med* 2004; 140:650-658. [abstracted in the New York Times; Web MD]
24. Langa KM, Valenstein MA, Fendrick AM, Kabeto MU, Vijan S. Informal caregiving for older Americans with symptoms of depression. *Am J Psychiatry* 2004; 161:857-863.
25. Krein SL, Klamerus ML, Vijan S, Lee J, Fitzgerald JT, Pawlow A, Reeves P, Hayward RA. The effectiveness of proactive diabetes case management for high-risk patients. *Am J Med* 2004; 116(11):732-739.
26. Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky JR, Selker HP. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. *J Clin Epidemiol* 2004; 57(8):843-852.
27. Vijan S, Inadomi J, Hayward RA, Hofer TP, Fendrick AM. Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the US. *Alimentary Pharmaceuticals and Therapeutics* 2004; 20:507-515.
28. Vijan S, Hayward RA, Langa KM. The impact of diabetes on work-force participation: results from a national household sample. *Health Serv Res* 2004; 39(6):1653-1669.
29. Vijan S, Stevens DL, Funnell MM, Herman WH, Lash RW. Management of Type 2 Diabetes Mellitus (Update). *Ann Arbor, MI: Office of Clinical Affairs, University of Michigan Health System*, 2004. [Available from the Agency for Healthcare Research and Quality at [www.guideline.gov](http://www.guideline.gov)] [practice guideline]

30. Bernstein SJ, Ruffin MT, Vijan S, Harrison RV, Standiford CJ. Adult Preventive Health Care: Cancer Screening (Update). *Ann Arbor, MI: Office of Clinical Affairs, University of Michigan Health System*, 2004. [Available from the Agency for Healthcare Research and Quality at [www.guideline.gov](http://www.guideline.gov)] [practice guideline]
31. Vijan S, Stuart N, Fitzgerald JT, Ronis DL, Hayward RA, Slater SS, Hofer TP. Barriers to following dietary recommendations in type 2 diabetes. *Diabetic Medicine* 2005; 22:32-38.
32. Nallamotheu BK, Saint S, Hofer TP, Vijan S, Eagle KA, Bernstein SJ. Hospital volume and outcome in coronary artery bypass grafting: A risk paradox? *Arch Intern Med* 2005; 165: 333-337.
33. Heisler M, Piette JD, Spencer M, Kieffer E, Vijan S. The relationship between knowledge of recent hemoglobin a1c values and diabetes care understanding and self-management. *Diabetes Care* 2005; 28(4):816-822.
34. Choe H, Mitrovich S, Dubay D, Hayward RA, Krein S, Vijan S. Proactive case management of high-risk patients with type 2 diabetes by a clinical pharmacist: a randomized controlled trial. *Am J Manag Care* 2005; 11:253-260.
35. Rosen AB, Hamel MB, Weinstein MC, Vijan S. Cost-effectiveness of Medicare coverage of angiotensin converting enzyme inhibitors for beneficiaries with diabetes. *Ann Intern Medicine*. 2005 July 19; 143:89-99. [abstracted by WebMD, Associated Press, United Press International, the Los Angeles Times, Reuters Health, National Public Radio] Winner of best paper, Society for Medical Decision-Making, 2005-2006.
36. Cram P, Vijan S, Katz D, Fendrick AM. Cost-effectiveness of in-home automated external defibrillators for individuals at increased risk of sudden cardiac death. *J Gen Intern Med* 2005; 20(3):251-258.
37. Vijan S, Hayward RA, Ronis DL, Hofer TP. The burden of diabetes therapy: implications for the design of effective treatment regimens. *J Gen Intern Med* 2005; 20:479-482.
38. Jones E, Vijan S, Fendrick AM, Deshpande S, Cram P. Automated external defibrillator deployment in public schools and senior centers. *Prehospital Emergency Care* 2005 October; 9(4):382-385.
39. Hayward RA, Kent DM, Vijan S, Hofer TP. Reporting clinical trial results to inform clinical practice: The need to assess benefits and harms for lower versus higher risk patients. *Health Affairs* 2005 November/December; 24(6):1571-1581.
40. Davis EN, Chung KC, Kotsis SV, Lau FH, Vijan S. Cost-utility analysis of cast immobilization versus open reduction and internal fixation for acute non-displaced mid-waist scaphoid fractures. *Plast Reconstr Surgery* 2006; 117:1223-1235.

41. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. *BMC Medical Research Methodology* 2006; 6:18.
42. Cutler DM, Rosen AB, Vijan S. Value of medical spending in the United States, 1960-2000. *N Engl J Med* 2006; 355(9):920-927. [Abstracted in The Wall Street Journal, the New York Times, Associated Press].
43. Hayward RA, Hofer TP, Vijan S. There is no valid epidemiological evidence for or against titrating lipid therapy to proposed LDL goals. A solvable problem. *Ann Intern Med* 2006; 145(7):520-530. [Abstracted in the New York Times].
44. Chan P, Vijan S, Morady F, Oral H. Cost-effectiveness of left atrial catheter ablation of atrial fibrillation. *J Am Coll Cardiol* 2006; 47(12):2513-2520.
45. Chan P, Fendrick AM, Bloomfield DM, Stein K, Bigger TJ, Vijan S. Cost-effectiveness of ICD therapy and risk stratification with microvolt T-wave alternans testing in the MADIT-II population. *J Am Coll Cardiol* 2006; 48(1):112-121.
46. Cram P, Katz D, Vijan S, Kent DM, Langa KM, Fendrick AM. Implantable or external defibrillators for individuals at increased risk of sudden cardiac death: Where cost-effectiveness hits fiscal reality. *Value in Health* 2006; 9(5):292-302.
47. Vijan S. Should we abandon QALYs ready as a resource allocation tool? *Pharmacoeconomics* 2006; 234(10):953-955.
48. Rein DB, Wirth K, Hoerger TJ, McCall N, Zhang P, Vijan S, Saadine J. The economic burden of adult visual disorders in the United States. *Arch Ophthalmol* 2006; 124:1754-1760.
49. Chan P, Chow T, Kereiakes D, Schloss EJ, Waller T, Eagle K, Hayward RA, Vijan S. Mortality reduction by prophylactic ICD placement in ischemic cardiomyopathy patients: An effectiveness study. *Arch Intern Med* 2006; 166(20):2228-2233.
50. Rosen AB, Cutler DM, Vijan S. Trends in the value of coronary heart disease care in the US. 1987-2002. *Health Affairs* 2007; 26:111-123.
51. Vijan S, Hwang I, Choi JR, Napierkowski J, Koff J, Inadomi J, Pickhardt P, Wong R. The cost-effectiveness of virtual colonoscopy in screening for colorectal cancer. *Am J Gastroenterol* 2007; 102:380-390.
52. Schmittiel J, Vijan S, Fireman B, Elston-Lafata J, Oestericher N, Selby JV. Using quality-adjusted life-years to measure the clinical benefit and value of diabetes care. *Med Care* 2007; 45(4):315-321.
53. Janz NK, Lakhani I, Vijan S, Katz SJ. Barriers and preferences for colorectal cancer screening. *Prev Med* 2007; 44(5):452-458.

54. Chan P, Nallamotheu BK, Gurm HS, Hayward RA, Vijan S. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. *Circulation* 2007; 115(18):2398-2409.
55. Kim C, Herman WH, Vijan S. Efficacy and cost of postpartum screening strategies for diabetes among women with histories of gestational diabetes. *Diabetes Care* 2007; 30(5): 1102-1106.
56. Tunceli K, Bradley CJ, Elston-Lafata J, Pladevall M, Divine G, Goodman A, Vijan S. Glycemic control and absenteeism among individuals with diabetes. *Diabetes Care* 2007; 30(5):1283-1285.
57. Shekelle P, Vijan S. Quality indicators for the care of diabetes in vulnerable elders. *J Am Geriatr Soc* 2007; 55 S2:S312-317.
58. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK. Glycemic Control and Type 2 Diabetes Mellitus: The optimal A1c Targets. A Guidance Statement from the American College of Physicians. *Ann Intern Med* 2007; 147(6):417-422.
59. Krein SL, Bernstein SJ, Fletcher CE, Makki F, Goldzweig CL, Watts B, Vijan S, Hayward RA. Improving eye care for veterans with diabetes: an example of using the QUERI steps to move from evidence to practice. *Implement Sci* 2008; 3:18. PMCID: PMC2277434.
60. Volk M, Vijan S, Marrero J. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. *Am J Transplant* 2008; 8(4):839-846. PMCID: Not Required.
61. Volk M, Lok AS, Ubel PA, Vijan S. Beyond utilitarianism: a method for analyzing competing ethical principals in a decision analysis of liver transplantation. *Medical Decision Making* 2008; 28(5):763-772. PMCID: Not Required.
62. Zulman D, Vijan S, Omenn GS, Hayward RA. The relative merits of population-based and targeted prevention strategies. *Milbank Quarterly* 2008; 86(4):557-580. NIHMSID: NIHMS97662.
63. Vijan S, Hayward RA, Ubel PA. Will running the numbers first violate the principles of patient-centered care? *Ann Intern Med* 2008; 149(11):839; author reply 840-841. PMCID: Not Required.

#### Manuscripts Submitted for Publication

1. Nerenz DR, Joseph C, Williams K, Elston-Lafata J, Moon C, Vijan S. Population health effects of eliminating racial/ethnic disparities in quality of care. *Submitted to Health Affairs*.
2. Saini SD, Schoenfeld P, Vijan S. Cost-effectiveness of surveillance colonoscopy in patients with a history of adenomatous polyps. *Submitted to Gastroenterology*.

3. Vijan S. Regression-based multivariable sensitivity analyses of Markov and Monte Carlo models. *Submitted to Medical Decision Making.*
4. Vijan S., Timbie J. Using quality-adjusted life-years to improve quality measurement. *Submitted to Health Affairs.*
5. Saini SD, Volk ML, Schoenfeld P, Vijan S. The clinical and economic effects of a pay-for-performance measure linking colonoscopy reimbursement to colonoscopy withdrawal time in patients with a personal history of adenomas. *Submitted to Gastroenterology.*
6. Rosen AB, Cutler DM, Vijan S. Conflicting patient and physician incentives for value. *Submitted to Health Affairs.*
7. Rosen AB, Alshanqeety O, Cutler DM, Vijan S. International trends in the value of healthcare spending: 1980-2000. *Submitted to New England Journal of Medicine.*
8. Fazel R, Shaw LJ, Vijan S. Cost-effectiveness of percutaneous alcohol septal ablation compared to surgical myectomy for treatment of hypertrophic obstructive cardiomyopathy. *Submitted to Circulation.*

#### Non-peer Reviewed Publications

1. Vijan S. *Is optimal glucose control worthwhile?* Patient Care 1998; 32(3):23-4.
2. Hayward RA, Vijan S. *Diabetes Care Priorities: Preventing Cardiovascular Complications.* VA Practice Matters, May 2000; 5(I).
3. Vijan S. The use of statin therapy in type 2 diabetes. *Diabetes Self-Management*; September/October 2004, p. 65.
4. Vijan S. Individualizing screening. *VA HSR&D FORUM.* May, 2006.
5. Vijan S. When should we stop screening? *VA HSR&D FORUM.* May, 2006.

#### Book chapters/Web-based educational modules/Monographs

1. Vijan S. *Diagnosis and management of type 2 diabetes.* American College of Physician PIER modules. American College of Physicians; published in web form, 2002. Available at <http://pier.acponline.org>
2. Vijan S. The cost-utility of screening for diabetic retinopathy. In: Stichwort: Diabetes. Documentation of an International Symposium. Bonn: mbH & Co, 2002. Pages 37-43.

3. Vijan S. Overview of the Vijan Colorectal Cancer Screening Model. In: Economic Models of Colorectal Cancer Screening in Average-Risk Adults. Eds: Pignone M, Russell L, Wagner J. Washington DC: National Academies Press, 2005. Pages 105-117.
4. NIH Consensus Statement on Celiac Disease. *NIH Consensus State Sci Statements*. 2004 June 28-30; 21(1): 1-22.
5. Vijan S. Hypertension in Diabetes. *BMJ Clinical Evidence*. 2005. Online at <http://www.clinicalevidence.com/ceweb/conditions/dia/0608/0608.jsp>

#### Abstracts (partial listing)

1. Vijan S., Hofer TP, Hayward RA. *The benefits of glycemic control in type diabetes.*
2. Vijan S., Hwang E, Hofer TP, Hayward RA. *Screening strategies for colon cancer: flexible sigmoidoscopy and fecal occult-blood testing versus colonoscopic screening*
3. Vijan S., Hofer TP, Hayward RA. *Screening intervals for diabetic retinopathy: are current guidelines justifiable?*
4. Ronis DL, Vijan S., Hayward RA, Phillips CV, Hofer TP. *Diabetes patients' views of treatments.*
5. Stuart N, Vijan S., Ronis D, Hayward RA. *Patient preferences for the care of diabetes.*
6. Wamsteker E-J, Vijan S. *The cost-effectiveness of carotid endarterectomy in patients with symptomatic 50 to 69% stenoses*
7. Vijan S., Zeber J, Valenstein M. *Should we screen for depression in primary care? A cost-utility analysis.*
8. Kent DM, Vijan S., Hayward RA, Griffith JL, Beshansky J, Selker HP. *Effectiveness and cost-effectiveness of t-PA relative to streptokinase in 921 patients treated with thrombolytic therapy: potential clinical and economic benefits of targeting therapy.*
9. Kent DM, Griffith JL, Hayward RA, Vijan S., Beshansky J, Califf RM, Selker HP. *An independently-derived model for selecting patients likely to benefit from tissue plasminogen activator: Validating with GUSTO.*
10. Vijan S., Fitzgerald JT, Stuart N. *Patient attitudes towards diet in type 2 diabetes.* Diabetes 2000;49:A446.
11. Fitzgerald JT, Vijan S., Stuart N. *Insulin therapy and patient attitudes at two VA Centers.* Diabetes 2000;49:A445.



12. Vijan S, Langa K, Stuart N, Hayward RA. *Racial variation in disability in type 2 diabetes.*
13. Vijan S, Langa K, Stuart N, Hayward RA. *Rates, causes, and costs of disability in patients with type 2 diabetes: results from a national sample.*
14. Zeber J, Vijan S, Valenstein M. *Cost-utility of depression screening: usual care versus collaborative treatment.*
15. Krein SL, Klamerus ML, Vijan S, Pawlow A, Reeves P, Hayward RA. *Proactive diabetes case management: expectation versus reality.*
16. Davis JA, Krein SL, Kerr EA, Vijan S, Hayward RA. *Evaluating a VISN-wide multi-faceted intervention to improve diabetes care.*
17. Vijan S, Inadomi J, Fendrick AM, Hofer TP, Hayward RA. *The impact of colorectal cancer screening recommendations on colonoscopy demand.*